Cogent Biosciences, Inc.
Cogent Biosciences, Inc. (COGT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cogt · stock forecast · 12 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$60.00
Consensus
$49.40
+58.8% upside
Low
$35.00
Median: $52 · Last Close: $31.11
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$49.40
58.8% upside
High Target
$60
92.9%
Low Target
$35
12.5%
Current Price
$31.11
as of today
Based on analyst price targets, the COGT stock price prediction for the next 12 months ranges from $35 to $60. The consensus COGT price forecast of $49.40 implies 58.8% upside from the current price of $31.11.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $30.31 | ↓ 2.55% |
1-day model range: $30.17–$30.45. Peak: $30.45 (-2.55%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · COGT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-29 | Wedbush | Maintains | Outperform→Outperform |
| 2026-05-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-17 | Wedbush | Maintains | Outperform→Outperform |
| 2026-02-18 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-01-21 | Wedbush | Maintains | Outperform→Outperform |
| 2026-01-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-19 | JP Morgan | Maintains | Overweight→Overweight |
| 2025-12-08 | Needham | Maintains | Hold→Hold |
| 2025-11-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-11 | Baird | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Cogent Biosciences, Inc. (COGT) stock. Of the recent 84 rating actions, 0 were upgrades and 3 were downgrades. 12 analysts currently cover COGT.
Analyst Recommendation Trends
COGT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$11M
↓ 98.5% YoY
Revenue Next Year
$345M
↑ 3083.3% YoY
EPS This Year
$-2.25
EPS Next Year
$-0.78
↓ 65.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast COGT EPS of $-2.25 for the current fiscal year, based on estimates from 9 analysts. The COGT revenue forecast is $11M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The COGT stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus COGT price target is $49.40 (+58.8% upside), with an analyst consensus of Buy.
The COGT short-term stock prediction for tomorrow is $30.31 (-2.55%).
Cogent Biosciences, Inc. trades on NASDAQ under the ticker COGT. The COGT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 83% of covering analysts.
Frequently asked questions
COGT forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month COGT price target is $49.40, with a high forecast of $60.00 and a low of $35.00. The median price target is shown in the chart above when available. This implies +58.8% potential upside from the current price of $31.11.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.